Clinical Trial Update: Unravelling Intestinal Fibrosis in Ulcerative Colitis [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial assessing a fibroblast activation protein inhibitor for intestinal fibrosis in ulcerative colitis, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Bowel Disease
• Ulcerative Colitis

Drugs mentioned

• Fibroblast Activation Protein Inhibitor

Snippet

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Conditions: Ulcerative Colitis (UC), Inflammatory Bowel Disease (IBD) | Phase 2, Phase 3 | Status: RECRUITING